-
公开(公告)号:US20170290841A1
公开(公告)日:2017-10-12
申请号:US15514259
申请日:2015-09-25
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO
IPC: A61K31/551 , A61K33/42 , A61K9/00 , A61K31/435
CPC classification number: A61K31/551 , A61K9/0048 , A61K9/08 , A61K31/435 , A61K33/42 , A61K47/18
Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a quaternary ammonium surfactant.
-
公开(公告)号:US20230190712A1
公开(公告)日:2023-06-22
申请号:US18172855
申请日:2023-02-22
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO , Akito MINAMIZONO
CPC classification number: A61K31/423 , A61K47/02 , A61K47/10 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/38 , A61K9/16
Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-6): (B-1) a cellulose ether species; (B-2) a starch species; (B-3) a povidone species; (B-4) a silicic acid compound; (B-5) a polyhydric alcohol; and (B-6) an alkyl sulfate ester.
-
公开(公告)号:US20170266080A1
公开(公告)日:2017-09-21
申请号:US15514020
申请日:2015-09-25
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO
IPC: A61J1/14 , A61K9/08 , A61K31/551
CPC classification number: A61J1/1468 , A61K9/08 , A61K31/551
Abstract: A technique is provided for suppressing discoloration of an aqueous composition containing a halogenated isoquinoline derivative during preservation at high temperature. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by Formula (1), wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a container made of polyolefin-based resin.
-
公开(公告)号:US20220096443A1
公开(公告)日:2022-03-31
申请号:US17418518
申请日:2019-12-27
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO , Akito MINAMIZONO , Chisa NISHIDA
IPC: A61K31/423 , A61K47/32 , A61K47/38
Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) and (B-7): (B-1) an alkylcellulose and a salt thereof; and a (meth)acrylic acid-based polymer.
-
公开(公告)号:US20200179346A1
公开(公告)日:2020-06-11
申请号:US16627128
申请日:2018-06-29
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO , Akito MINAMIZONO
Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition contains pemafibrate, a salt thereof or a solvate thereof in an amount of 0.017 to 4.2 mass % in terms of a free form of pemafibrate with respect to the total mass of the pharmaceutical composition.
-
公开(公告)号:US20220151996A1
公开(公告)日:2022-05-19
申请号:US17591108
申请日:2022-02-02
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO , Akito MINAMIZONO
IPC: A61K31/423
Abstract: Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and has excellent stability. A pharmaceutical composition is provided containing pemafibrate, a salt thereof or a solvate thereof and having a moisture content of 2.4 mass % or less.
-
公开(公告)号:US20200155514A1
公开(公告)日:2020-05-21
申请号:US16627141
申请日:2018-06-29
Applicant: KOWA COMPANY, LTD.
Inventor: Shin SUGIMOTO , Akito MINAMIZONO
IPC: A61K31/423 , A61K47/26 , A61K47/38
Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided containing the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a disaccharide species.
-
-
-
-
-
-